Jul. 31 at 4:30 PM
$RGNX $CLSD Abbvie comments today on the Regenxbio...kinda positive yet I don't see the DR trial starting this year based on the answer:
____________
"Your question on eye care, I mean our focus on eye care is in glaucoma, retinal disease, and prescription dry eye.
It has very much a scientific focus. It's a data-driven business. It's a very efficient business as well. And obviously, we're excited about the REGENXBIO Gene Therapy Program focused on wet AMD and diabetic retinopathy.
Depending on how that plays out, I think you could see that as becoming a stronger growth driver. We obviously have four of the five, as you think about, you get a lot of questions there.
But we don't get as many questions on eye care, but we do believe as you start to get more visibility to this REGENXBIO Program, you'll likely spend more time focusing on it. We think of it as a potential to be a long-term growth driver for the company.
And we like the fit it has for AbbVie."
https://www.fool.com/earnings/call-transcripts/2025/01/31/abbvie-abbv-q4-2024-earnings-call-transcript/
